Identifying molecular changes associated with disease is only the beginning. Understanding which changes may represent meaningful therapeutic targets requires a deeper understanding of the underlying biology.

In a new interview with Drug Target Review, Dr Shi-qi An, Director of Marketing and Science Communications at Novogene Europe, shares her perspectives on how multiomics approaches can support drug target identification and validation, following discussions at ELRIG Drug Discovery 2026.11

The article explores how integrating genomics, transcriptomics, proteomics and metabolomics can provide complementary evidence for investigating disease mechanisms. It also examines how single-cell and spatial technologies can reveal cellular heterogeneity, tissue context and potential therapeutic vulnerabilities that may be overlooked by conventional bulk analysis.

Drawing on published research into acquired resistance to targeted cancer therapies, the discussion highlights how integrated molecular analysis can help researchers investigate the mechanisms behind treatment resistance.

Importantly, the article also addresses the challenges of multiomics integration, emphasising the importance of experimental design, biological interpretation and functional validation in translating molecular findings into meaningful research directions.

Read the full article on Drug Target Review:

How multiomics can strengthen drug target discovery